The University of Edinburgh
Assessing gene therapy application in a mouse model of PTEN hamartoma tumour syndrome
Abstract
dc:description.abstractPhosphatase and tensin homolog deleted on chromosome ten (PTEN) is a key tumour suppressor protein with widespread expression across cell types and within cell compartments, primarily working in the PI3K/AKT/mTOR signalling pathway to regulate cell growth, progression and survival. Beyond its role in regulating the cell cycle, PTEN also performs diverse functions, including functioning as a scaffolding protein and acting in different pathways that regulate cell-to-cell contact dynamics, cell migration, and genomic stability. Germline PTEN mutations have been identified in various inherited tumour-predisposing syndromes with overlapping features, including Cowden syndrome (CS), Lhermitte–Duclos disease (LD), Bannayan–Riley–Ruvalcaba syndrome (BRRS), Proteus and Proteus-like syndrome (PS). Beyond cancer, PTEN has a role in the aetiology of cases of autism spectrum disorder (ASD) associated with macrocephaly. Consequently, these diverse disorders linked to germline PTEN mutations have been collectively termed PTEN Hamartoma Tumour Syndrome (PHTS). The predominant symptoms encompass dermatological lesions such as multiple trichilemmomas, lipomas, fibromas, and papillomas, alongside gastrointestinal polyps, an elevated risk of carcinoma, and macrocephaly. Currently, there is no approved curative treatment for PHTS patients. However, research on pharmacological interventions targeting PTEN downstream signalling (the PI3K/AKT/mTOR) is under development. Despite promising initial results, concerns persist regarding potential drug resistance and the occurrence of significant adverse events, limiting the application of such products. The lack of effective treatment necessitates lifelong cancer surveillance and screening for PHTS patients to enable early tumour discovery and treatment. Based on this high level of unmet clinical need, gene therapy targeting the underlying cause of PTEN deficiency is considered a rational therapeutic strategy. This is an attractive strategy given it would address the diverse functions of PTEN. Moreover, the gene is small and readily packaged in therapeutic vectors and the protein can be secreted which would further facilitate delivery. As such, the focus of the research in this thesis is to develop and assess a strategy for gene therapy as a treatment option in PHTS. I hypothesised that the restoration of PTEN levels through stable expression of a PTEN transgene cassette delivered using an adeno-associated virus (AAV) vector would prevent the occurrence and development of tumours and ameliorate the development of PTEN-related neurodevelopmental impairments. To evaluate this hypothesis, a human PTEN-expressing AAV vector was designed, and its therapeutic effects were assessed in a murine model of PHTS; heterozygous for germline PTEN mutation. As a first step, I characterized our germline PTEN heterozygous mouse model, focusing on tumour onset and incidence, as well as neurological and behavioural phenotypes to be able to determine putative outcome measures to evaluate the efficacy of PTEN gene therapy cassette. Notably, PtenΔ5/+ female mice consistently exhibited an earlier onset of tumour development compared to male PtenΔ5/+ mice during gross observation. By 36 weeks of age, only 25% of PtenΔ5/+ males showed detectable tumour burden, whereas all PtenΔ5/+ females (100%) developed palpable tumours. Additionally, the kinetics of tumour growth were higher in PtenΔ5/+ females over the study period. Subsequent histological assessment revealed all subcutaneous lumps observed in mice to be lymph node tumours and occasional mammary gland tumours. In terms of behavioural phenotypes, PtenΔ5/+ mice did not exhibit abnormal behavioural changes compared to WT mice across various behavioural tests defined in this thesis including motor and anxiety phenotypes. However, macrocephaly was a robust phenotype in both male and female PtenΔ5/+ mice. Consequently, the study was narrowed to focus on the evaluation of PTEN gene therapy on PtenΔ5/+ female mice. Subsequently, I evaluated the therapeutic potential of the AAV9/CBh-hPTEN gene construct in preventing or ameliorating PHTS-like phenotypes in PtenΔ5/+ female mice. Systemic delivery of AAV9/CBh-hPTEN at doses of 5E11 vg/mouse and 2E12 vg/mouse via tail vein injection into 5-week-old PtenΔ5/+ heterozygous female mice was conducted. Experimental mice were monitored in a blinded fashion for the development and progression of gross/palpable tumours over 9 months. Surprisingly, systemic delivery of AAV9/CBh-hPTEN showed no impact on tumour development and progression in PtenΔ5/+ mice at the doses tested. This outcome is attributed to the low levels of transgene expression in lymph nodes, where tumour development was most penetrant in PtenΔ5/+ mice. Similarly, no effects were detected for macrocephaly phenotypes, likely due to the low levels of transgene expression in the brain following systemic intravenous injection. An evaluation of transgene expression using immunoblot analysis showed a robust and dose-dependent expression of vector-derived PTEN in the liver. The most overt liver phenotypes in the PtenΔ5/+ mice were focal liver steatosis (pre-cancerous lesion) and monocytic infiltration. Both of these observed liver pathologies were significantly reduced in the liver of vector-treated PtenΔ5/+ heterozygous mice with a dose-dependent effect. Intending to further assess the further therapeutic potential of the PTEN gene therapy construct, I assessed the impart of neonatal dosing on the macrocephaly phenotype. PtenΔ5/+ mice were dosed by intracerebroventricular delivery of vector at postnatal day 1., P01-old mice underwent intracranial delivery of the AAV9/CBh-hPTEN construct using two different doses, 5E10 and 1E11 vg/mouse. The results demonstrated a dose-dependent reduction in brain size in mice treated with the therapeutic construct compared to the vehicle (PBS) -treated control group. Consistent with earlier findings, experimental groups undergoing a social preference test confirmed the absence of a genotype effect, limiting the assessment of neurological phenotypes to anatomical assessments. In summary, I identified a gender bias in peripheral tumour incidence and development in the germline PTEN heterozygous mouse model. Notably, PtenΔ5/+ females exhibit a more expedited disease-relevant genotype effect, making them more practical for evaluating the potential benefits of PTEN gene therapy cassettes. A key finding of the tumour analyses was to demonstrate the inability of AAV9/CBh-hPTEN to impact the lymph node tumours that dominate this phenotype in mice. This was a limitation of effective translational biodistribution rather than the effectiveness of the transgene cassette. Where tissue distribution was more effective, the AAV9/CBh-hPTEN could normalise aberrant brain growth and reduce the severity of liver pathologies including steatosis and monocytic infiltration. Overall, the results emphasise the need to develop better vector technology to effectively target key cell and tissue types that drive the PHTS phenotype.
Degree
thesis:*- Grantor dc:publisher
- The University of Edinburgh
- Year dc:date.issued
- 2024
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Erdem, Ceren
- Advisors dc:contributor.advisor
-
- Cobb, Stuart
- Kind, Peter
- Gadalla, Kamal
- Osterweil, Emily
Subjects
dc:subject × 6Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- http://dx.doi.org/10.7488/era/4663